1,506 results on '"Stewart, A. Keith"'
Search Results
2. Integrated analysis of next generation sequencing minimal residual disease (MRD) and PET scan in transplant eligible myeloma patients
3. Correction: Integrated analysis of next generation sequencing minimal residual disease (MRD) and PET scan in transplant eligible myeloma patients
4. Management of Newly Diagnosed Multiple Myeloma Today, and in the Future
5. Contributors
6. Health-related quality of life in patients given ciltacabtagene autoleucel for relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b–2, open-label study
7. Germline Cancer Susceptibility Gene Testing in Unselected Patients With Colorectal Adenocarcinoma: A Multicenter Prospective Study
8. Selective Inhibition of Nuclear Export With Oral Selinexor for Treatment of Relapsed or Refractory Multiple Myeloma
9. Alu-dependent RNA editing of GLI1 promotes malignant regeneration in multiple myeloma.
10. Distribution of clonal hematopoiesis of indeterminate potential (CHIP) is not associated with race in patients with plasma cell neoplasms
11. Continuous Elotuzumab, Pomalidomide, and Dexamethasone Maintenance Following Second Autologous Transplantation for Multiple Myeloma: Results of a Prospective Phase 2 Multicenter Trial
12. Deconstructing the Rose Metaphor and Cultivating Trees of Rebellion in Sandra Cisneros’s The House on Mango Street
13. Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study
14. Targeting the Otub1/c-Maf axis for the treatment of multiple myeloma
15. Impact of integrated translational research on clinical exome sequencing
16. A Landmark Paper That Introduced Proteasome Inhibition in Myeloma
17. Genome-wide detection of tandem DNA repeats that are expanded in autism
18. MYC dysregulation in the progression of multiple myeloma
19. Clinical Impact of Pathogenic Germline Variants in Pancreatic Cancer: Results From a Multicenter, Prospective, Universal Genetic Testing Study
20. Identification of novel mutational drivers reveals oncogene dependencies in multiple myeloma
21. Treatment With Bortezomib-based Therapy, Followed by Autologous Stem Cell Transplantation, Improves Outcomes in Light Chain Amyloidosis: A Retrospective Study
22. Ixazomib, lenalidomide, and dexamethasone in patients with newly diagnosed multiple myeloma: long-term follow-up including ixazomib maintenance
23. Spectrum and functional validation of PSMB5 mutations in multiple myeloma
24. A high-risk, Double-Hit, group of newly diagnosed myeloma identified by genomic analysis
25. Prognostic Validation of SKY92 and Its Combination With ISS in an Independent Cohort of Patients With Multiple Myeloma
26. Data from Perspectives on the Risk-Stratified Treatment of Multiple Myeloma
27. Supplementary Table from Perspectives on the Risk-Stratified Treatment of Multiple Myeloma
28. Supplement 2. Next generation sequencing results for first round screen from CRISPR Genome-Wide Screening Identifies Dependence on the Proteasome Subunit PSMC6 for Bortezomib Sensitivity in Multiple Myeloma
29. Data from CRISPR Genome-Wide Screening Identifies Dependence on the Proteasome Subunit PSMC6 for Bortezomib Sensitivity in Multiple Myeloma
30. Data from Proteasome Subunits Differentially Control Myeloma Cell Viability and Proteasome Inhibitor Sensitivity
31. Supplement 5. A total of 36 mutations in 19S proteasome subunits out of 895 patients were identified in CoMMpass study. from CRISPR Genome-Wide Screening Identifies Dependence on the Proteasome Subunit PSMC6 for Bortezomib Sensitivity in Multiple Myeloma
32. Figure S1 from CRISPR Genome-Wide Screening Identifies Dependence on the Proteasome Subunit PSMC6 for Bortezomib Sensitivity in Multiple Myeloma
33. Supplement 1. sgRNA sequences targeting PSMC1 to C6 from CRISPR Genome-Wide Screening Identifies Dependence on the Proteasome Subunit PSMC6 for Bortezomib Sensitivity in Multiple Myeloma
34. Supplement 3. sgRNA sequences used for second round screen. from CRISPR Genome-Wide Screening Identifies Dependence on the Proteasome Subunit PSMC6 for Bortezomib Sensitivity in Multiple Myeloma
35. FigureS2 from CRISPR Genome-Wide Screening Identifies Dependence on the Proteasome Subunit PSMC6 for Bortezomib Sensitivity in Multiple Myeloma
36. Supplementary Figures 1-9, Supplementary Tables 1-3 from Proteasome Subunits Differentially Control Myeloma Cell Viability and Proteasome Inhibitor Sensitivity
37. Supplemental Figure legends from CRISPR Genome-Wide Screening Identifies Dependence on the Proteasome Subunit PSMC6 for Bortezomib Sensitivity in Multiple Myeloma
38. Supplement 4. Next generation sequencing results for second round screen. from CRISPR Genome-Wide Screening Identifies Dependence on the Proteasome Subunit PSMC6 for Bortezomib Sensitivity in Multiple Myeloma
39. Table S1: IC50 (nM) for M cells deleted PSMC subunits treated with BTZ from CRISPR Genome-Wide Screening Identifies Dependence on the Proteasome Subunit PSMC6 for Bortezomib Sensitivity in Multiple Myeloma
40. Supplementary Data from Proteasome Subunits Differentially Control Myeloma Cell Viability and Proteasome Inhibitor Sensitivity
41. Supplementary table 2 from Loss of FAM46C Promotes Cell Survival in Myeloma
42. Supplementary Table S1 from Determinants of sensitivity to lovastatin-induced apoptosis in multiple myeloma
43. Supplementary Table S3 from Genome-Wide Analysis Uncovers Novel Recurrent Alterations in Primary Central Nervous System Lymphomas
44. Spplementary table 1 from Loss of FAM46C Promotes Cell Survival in Myeloma
45. supplementary figures from Loss of FAM46C Promotes Cell Survival in Myeloma
46. Supplementary Figures S1-S3 from Genome-Wide Analysis Uncovers Novel Recurrent Alterations in Primary Central Nervous System Lymphomas
47. Data from Loss of FAM46C Promotes Cell Survival in Myeloma
48. Supplementary table 3 from Loss of FAM46C Promotes Cell Survival in Myeloma
49. Data from Determinants of sensitivity to lovastatin-induced apoptosis in multiple myeloma
50. Supplementary table 5 from Loss of FAM46C Promotes Cell Survival in Myeloma
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.